Aktienanalyse zu Verastem Inc (VSTM)VSTMVerastem Inc

Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Verastem Inc (VSTM) is a good buy right now, trading at $8.65 with a recent price target increase to $22 from Alliance Global, indicating a potential upside of over 154%. The stock has shown a positive momentum with a 20-day change of +16.26% and a solid RSI of 58.205, suggesting it is neither overbought nor oversold. The main risk is the company’s ongoing net losses, with a net income of -34,673,000 in Q2 2026, which could affect future performance if not addressed.

5 analysts cover VSTM: 4 rate it Buy, 1 Hold and 0 Sell. The average price target is 15.60.